Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study

BACKGROUND AND AIM: Sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucose-lowering drugs that increase urinary glucose excretion have been shown to reduce CV events in patients with type 2 diabetes (T2D). Furthermore, several studies have demonstrated that treatment with SGLT2 inhibitors affect...

Descripción completa

Detalles Bibliográficos
Autores principales: Rau, Matthias, Thiele, Kirsten, Hartmann, Niels-Ulrik Korbinian, Möllmann, Julia, Wied, Stephanie, Hohl, Mathias, Marx, Nikolaus, Lehrke, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857445/
https://www.ncbi.nlm.nih.gov/pubmed/35242892
http://dx.doi.org/10.1016/j.bonr.2022.101175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857445/
https://www.ncbi.nlm.nih.gov/pubmed/35242892
http://dx.doi.org/10.1016/j.bonr.2022.101175

Ejemplares similares